Eli Lilly reported second-quarter earnings and revenue that significantly exceeded analyst expectations, driven by strong sales of the diabetes drug Mounjaro and weight loss injection Zepbound. Mounjaro sales were over $3 billion for the quarter, more than triple the prior year and beating estimates. Zepbound sales exceeded $1 billion, above estimates of nearly $900 million. Shares jumped over 9% pre-market on the strong results and outlook increase. Eli Lilly is the largest U.S.-based pharmaceutical company with a market cap of over $730 billion.
Category
🗞
NewsTranscript
00:00It's Benzinga and here's what's on the block.
00:02Eli Lilly reported second quarter earnings and revenue that significantly exceeded analysts'
00:07expectations driven by strong sales of the diabetes drug Monjaro and weight loss injection
00:12ZepBound.
00:13Monjaro sales were over $3 billion for the quarter, more than triple the prior year and
00:17beating estimates.
00:18ZepBound sales exceeded $1 billion, above estimates of nearly $900 million.
00:24Shares jumped over 9% pre-market on the strong results and outlook increase.
00:28Eli Lilly is the largest U.S.-based pharmaceutical company with a market cap of over $730 billion.
00:34For all things money, visit Benzinga.com.